Effects of IL-1β inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial.

In patients with CH mutations (n = 279), a similar treatment effect due to canakinumab treatment was observed, but the difference did not reach statistical significance, likely because of the lower sample size: HR = 0.77 (95% CI, 0.49-1.19); P = .238 ( supplemental Figure 1 B, right).

also in 111,027 other papers

16 In our analysis, canakinumab treatment showed a trend toward a higher decrease of IL-6 and hepcidin levels and was significantly associated with a higher hematological response in patients bearing TET2 mutations.

also in 53,322 other papers

When the effect of canakinumab treatment was analyzed in patients stratified based on individual CH mutations, patients with TET2 mutations showed a nonsignificant trend for a more pronounced reduction in IL-6 and TNF-α levels compared with patients without CH mutations ( Figure 5 A).

also in 5,406 other papers